Shenzhen Zhongge Biotechnology Co. Ltd. has discovered NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, liver, cardiovascular, inflammatory, renal, metabolic and ...

NLRP3 is an inflammasome seeding pattern recognition receptor activated in response to multiple danger signals which perturb intracellular homeostasis. Electrostatic interactions between the NLRP3 ...

Colchicine has a unique anti-inflammatory mechanism: it is not only able to concentrate in leucocytes, especially neutrophils, and block tubulin polymerisation, affecting the microtubules assembly, ...

Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for inflammatory and neurodegenerative diseases, today announced that ...

This study is a significant advancement in developing innovative therapies for neurodegenerative diseases, according to Zydus ...

MiR-148a directly inhibited thioredoxin-interacting protein (TXNIP) expression. Consequently, treatment of hepatocytes with ethanol resulted in TXNIP overexpression, activating NLRP3 inflammasome and ...

Leading with practical insights from the best in the industry, the 4th Annual Inflammasome Therapeutics Summit is returning in person on November 29 – December 1 to Boston to equip you with the ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.